785 articles
A regenerative knee implant outperformed standard surgical care on pain, mobility, and function across five years — including in osteoarthritis patients.
Genflow Biosciences teams with LNP pioneer Acuitas to advance SIRT6 gene therapy delivery, a fully-funded deal signaling growing confidence in longevity biotech.
Belgian biotech Coultreon raises $125M to advance an oral SIK3 inhibitor that rebalances inflammation rather than suppressing immunity outright.
London biotech Endlyz raises Seed 2 funding to restore cellular cleanup systems linked to Parkinson's, aiming to slow disease — not just symptoms.
A tiny brain region called the CGIC acts as a pain switch. Silencing it prevented and even reversed chronic pain in animals.
New research links internalized stress and hopelessness to faster memory decline, pointing to a modifiable risk factor for cognitive aging.
Intellia's in vivo CRISPR treatment edits genes directly inside living patients and just cleared a Phase 3 trial — a world first.
Intellia Therapeutics reports a landmark Phase 3 win for CRISPR gene editing, potentially offering a one-time cure for a debilitating genetic disease.
A novel transcatheter mitral valve replacement system shows sustained valve performance and low complications at 1 year in early trial data.
The AVANT GUARD trial shows PFA nearly doubles success rates vs drugs for persistent atrial fibrillation, published in NEJM.
A 50,000-patient Danish study finds first-time seizures raise cancer risk 5x in year one, including non-neurologic cancers like lung and colorectal.
Updated EULAR guidelines demand physical activity counseling as standard arthritis care, backed by 100+ new studies including 30 RCTs.
